Last updated: February 19, 2026
Taiwan drug patent TW202400181, titled "FORMULATION OF ANGIOTENSIN II RECEPTOR BLOCKER AND PHOSPHODIESTERASE 5 INHIBITOR," describes a pharmaceutical composition containing an angiotensin II receptor blocker (ARB) and a phosphodiesterase type 5 (PDE5) inhibitor. The patent application was filed on March 16, 2023, by Y.W. PHARMACEUTICAL CO., LTD. and is currently in the examination stage. The invention aims to provide a fixed-dose combination (FDC) product offering synergistic therapeutic effects for cardiovascular conditions.
What is the Primary Therapeutic Indication Claimed?
The patent application broadly claims utility in treating cardiovascular diseases. Specifically, it targets conditions where both ARB and PDE5 inhibitor mechanisms are beneficial. This includes hypertension, heart failure, and potentially erectile dysfunction, particularly when co-occurring with cardiovascular risk factors. The synergy is expected to enhance vasodilation and reduce blood pressure more effectively than monotherapy.
What Specific Compounds are Covered by the Claims?
The patent claims cover classes of compounds rather than specific chemical entities, allowing for broad protection.
-
Angiotensin II Receptor Blockers (ARBs): The patent claims encompass ARBs that bind to the AT1 receptor. This includes, but is not limited to, well-established ARBs such as:
- Losartan
- Valsartan
- Olmesartan
- Telmisartan
- Irbesartan
- Candesartan
- Azilsartan
- Ramipril (though technically an ACE inhibitor, its classification and related therapeutic targets overlap, and the patent aims to block the angiotensin system broadly).
-
Phosphodiesterase Type 5 (PDE5) Inhibitors: The patent claims cover PDE5 inhibitors that inhibit the PDE5 enzyme. This includes, but is not limited to, compounds such as:
- Sildenafil
- Tadalafil
- Vardenafil
- Avanafil
The patent also explicitly mentions that other ARBs and PDE5 inhibitors not specifically enumerated but fitting the definitions of these classes are also within the scope of the claims.
What are the Key Formulation Aspects Claimed?
The core of TW202400181 lies in the fixed-dose combination formulation. The claims focus on a pharmaceutical composition containing:
- An effective amount of an ARB.
- An effective amount of a PDE5 inhibitor.
- At least one pharmaceutically acceptable excipient.
The patent details several critical formulation aspects:
- Dosage Ratios: While specific ratios are not mandated for all combinations, the patent suggests exploring various ratios to achieve optimal therapeutic outcomes and minimize side effects. For example, it contemplates ratios that allow for the standard therapeutic dosage of each active ingredient.
- Excipients: A wide range of pharmaceutically acceptable excipients are disclosed, enabling the creation of various dosage forms. These include:
- Diluents/Fillers: Lactose, microcrystalline cellulose, starch, dicalcium phosphate.
- Binders: Povidone, hydroxypropyl methylcellulose (HPMC), ethylcellulose.
- Disintegrants: Croscarmellose sodium, sodium starch glycolate, crospovidone.
- Lubricants: Magnesium stearate, stearic acid, talc.
- Glidants: Colloidal silicon dioxide.
- Coatings: Polymeric film coatings (e.g., HPMC-based), enteric coatings.
- Dosage Forms: The claims cover multiple dosage forms, including:
- Oral solid dosage forms (tablets, capsules).
- Controlled-release formulations designed to optimize pharmacokinetic profiles and reduce dosing frequency.
- Orally disintegrating tablets (ODTs).
- Stability: The patent emphasizes the development of formulations with enhanced stability, addressing potential incompatibilities between the active ingredients and excipients over the shelf life of the product.
What is the Significance of the Synergistic Effect Claimed?
The patent claims a synergistic therapeutic effect, meaning the combined effect of the ARB and PDE5 inhibitor is greater than the sum of their individual effects. This synergy is attributed to:
- Enhanced Vasodilation: Both ARBs and PDE5 inhibitors promote vasodilation. ARBs block the vasoconstrictive effects of angiotensin II, while PDE5 inhibitors increase intracellular cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and vasodilation. The combination amplifies this effect.
- Improved Blood Pressure Control: The synergistic vasodilation contributes to more effective reduction in blood pressure, potentially allowing for lower doses of each component or achieving therapeutic targets in patients resistant to monotherapy.
- Cardiovascular Protection: Beyond blood pressure reduction, the enhanced vasodilation and potential anti-inflammatory or anti-remodeling effects associated with both drug classes could offer superior cardioprotective benefits.
What is the Patent Landscape for ARB and PDE5 Inhibitor Combinations?
The patent landscape for fixed-dose combinations of ARBs and PDE5 inhibitors is active and competitive, with numerous patents and applications related to various combinations and formulations.
- Existing FDCs: Several ARB-PDE5 inhibitor combinations are already on the market or have been developed. For instance, combinations of sildenafil with various ARBs have been explored for hypertension and erectile dysfunction. Tadalafil is also part of FDCs with ARBs for cardiovascular indications.
- Formulation Innovation: A significant portion of the patent activity focuses on novel formulations to improve drug delivery, bioavailability, patient compliance, and stability. This includes:
- Patents covering specific ratios of active ingredients.
- Patents on controlled-release or extended-release formulations.
- Patents on orally disintegrating tablets.
- Patents addressing the chemical stability of the combined entities.
- Therapeutic Indications: While hypertension and erectile dysfunction are primary targets, research and patent applications are also exploring these combinations for:
- Pulmonary Arterial Hypertension (PAH).
- Heart Failure with Preserved Ejection Fraction (HFpEF).
- Renal Impairment.
- Post-Myocardial Infarction management.
Key Players and Their Patent Activities:
- Major Pharmaceutical Companies: Companies like Pfizer, Takeda, Merck, and various generic manufacturers have a strong presence in this therapeutic space, holding patents on specific combinations, formulations, or therapeutic uses.
- Contract Research Organizations (CROs) and Smaller Biotechs: These entities often develop novel formulations or explore new therapeutic applications for existing drug classes, filing patents on their innovations.
- Generic Manufacturers: Post-patent expiry, generic companies actively seek to develop and patent novel formulations or bioequivalent versions of FDCs to gain market share.
TW202400181's Position:
This specific patent application, TW202400181, seeks to claim a broad composition covering various ARBs and PDE5 inhibitors in a fixed-dose combination. Its novelty and patentability will depend on demonstrating a distinct inventive step over existing art, particularly concerning specific combinations of ARBs and PDE5 inhibitors, their synergistic effects, or novel formulation aspects that provide an unexpected advantage. The broad nature of the claims, covering classes of compounds, aims for wide market exclusivity if granted. However, it faces challenges from prior art that may have disclosed similar combinations or formulations.
What are the Potential Business Implications of This Patent?
The grant of TW202400181 could have significant implications for companies involved in cardiovascular drug development and commercialization.
- Market Exclusivity: If granted, the patent would provide Y.W. PHARMACEUTICAL CO., LTD. with a period of market exclusivity for fixed-dose combinations of ARBs and PDE5 inhibitors as claimed. This could prevent competitors from marketing similar products during the patent term.
- Licensing Opportunities: The patent holder could license the technology to other pharmaceutical companies, generating revenue through royalties and upfront payments.
- Defensive Patenting: Companies may seek to obtain similar patents for their own ARB-PDE5 inhibitor formulations to protect their market position or to use as leverage in cross-licensing agreements.
- Litigation Risk: Competitors developing FDCs of ARBs and PDE5 inhibitors would need to carefully assess the scope of TW202400181 to avoid infringement, potentially leading to litigation if their products are deemed to fall within the patent's claims.
- R&D Strategy: For R&D departments, this patent highlights a strategy for developing combination therapies. It encourages exploration of synergistic effects and novel formulations to create differentiated products.
- Investment Decisions: Investors assessing companies in the cardiovascular space would need to consider the patent portfolios, including applications like TW202400181, when evaluating potential investments and market opportunities. The strength and breadth of the claims will be crucial in this assessment.
The patent application's broad claims encompassing classes of drugs and various formulations suggest an intent to capture a significant portion of the potential market for ARB-PDE5 inhibitor FDCs. The examination process will scrutinize prior art to determine the patentability and enforceability of these claims.
What are the Next Steps in the Patent Prosecution Process?
The patent application TW202400181 is currently in the examination stage in Taiwan. The typical prosecution process involves:
- Substantive Examination: A patent examiner reviews the application to determine if it meets the requirements for patentability, including novelty, inventive step, and industrial applicability. This involves searching for prior art (existing patents, publications, etc.) that might anticipate or render obvious the claimed invention.
- Office Actions: If the examiner finds any issues with patentability (e.g., lack of novelty, obviousness over prior art), they will issue an "Office Action" detailing these objections.
- Applicant Response: The applicant (Y.W. PHARMACEUTICAL CO., LTD.) has a defined period to respond to the Office Action. This response may involve amending the claims, providing arguments against the examiner's objections, or submitting additional evidence.
- Further Examination: The examiner reviews the applicant's response and may issue further Office Actions or signal allowance.
- Allowance and Grant: If the examiner is satisfied that the application meets all patentability criteria, the patent will be allowed. The applicant will then pay the grant fee, and the patent will be officially granted and published.
- Post-Grant Opposition/Review: In some jurisdictions, third parties may have a period after grant to file an opposition or request for review of the patent.
Given the application was filed in March 2023, it is reasonable to expect an Office Action within the next 12-24 months, depending on the examination backlog at the Taiwan Intellectual Property Office (TIPO). The applicant's strategic responses to any objections will be critical in shaping the final scope and strength of the granted patent.
Key Takeaways
- Taiwan patent application TW202400181 seeks protection for fixed-dose combinations of Angiotensin II Receptor Blockers (ARBs) and Phosphodiesterase Type 5 (PDE5) Inhibitors.
- The claimed invention targets cardiovascular diseases, leveraging synergistic vasodilation effects for improved therapeutic outcomes.
- Claims cover broad classes of ARBs (e.g., losartan, valsartan) and PDE5 inhibitors (e.g., sildenafil, tadalafil), as well as various pharmaceutical formulations and dosage forms.
- The patent landscape for such combinations is competitive, with numerous existing patents and ongoing development.
- Successful grant of this patent could provide significant market exclusivity and licensing opportunities for the applicant, Y.W. PHARMACEUTICAL CO., LTD.
- The application is currently in the examination stage at the Taiwan Intellectual Property Office (TIPO), with potential for Office Actions and claim amendments.
Frequently Asked Questions
-
What is the primary benefit of combining an ARB with a PDE5 inhibitor as claimed in TW202400181?
The primary claimed benefit is a synergistic therapeutic effect, resulting in enhanced vasodilation and more effective blood pressure control for treating cardiovascular diseases, potentially offering superior outcomes compared to monotherapy.
-
Does the patent specify the exact dosages for the ARB and PDE5 inhibitor in the combination?
The patent claims cover "effective amounts" of each active ingredient, suggesting that specific dosage ratios will be explored and optimized. It does not mandate a single fixed dosage for all possible combinations.
-
What types of pharmaceutical formulations are covered by the patent?
The patent covers various oral dosage forms, including tablets and capsules, and also contemplates controlled-release formulations and orally disintegrating tablets (ODTs) to enhance drug delivery and patient compliance.
-
How does this patent application differ from existing ARB-PDE5 inhibitor combination products?
The patent's novelty and patentability will depend on demonstrating an inventive step over existing art. Its broad claims covering classes of compounds and various formulations aim for wider protection than patents on specific, already commercialized combinations.
-
What is the current status of patent application TW202400181?
The patent application is currently in the substantive examination stage at the Taiwan Intellectual Property Office (TIPO). This means a patent examiner is reviewing it against prior art to determine its patentability.
Citations
[1] Y.W. PHARMACEUTICAL CO., LTD. (2023). FORMULATION OF ANGIOTENSIN II RECEPTOR BLOCKER AND PHOSPHODIESTERASE 5 INHIBITOR. Taiwan Patent Application No. TW202400181.
